Artemether and Praziquantel a green light to treat the resistance schistosomiasis: A case Report

Omaima Abdel Majeed Mohamed Salih*1; Abdelsalam MA Nail 2; Ahmed Mudawi Musa 3; Elmugadam F A4; Abdelwaged Abdelrhman omer 5

doi:10.52981/ojps.v2i3.2870

Omaima Abdel Majeed Mohamed Salih*1 Associate Professor, Departments of Pediatrics and Child Health, Faculty of Medicine and Health Sciences, Omdurman Islamic University, Tropical Diseases Teaching Hospital.
Abdelsalam MA Nail 2 Associate Professor of Internal Medicine Department of Internal Medicine Faculty of Medicine and Health Sciences, Omdurman Islamic University, Tropical Diseases Teaching Hospital.
Ahmed Mudawi Musa 3 Professor of immunology and infectious diseases at the Institute of Endemic Diseases
Elmugadam F A4 Institute of Endemic Diseases - University of Khartoum
Abdelwaged Abdelrhman omer 5 Pediatric registrar, Mohammed A. Hamid’s Pediatrics Hospital, Omdurman, Sudan

DOI: https://doi.org/10.52981/ojps.v2i3.2870

Keywords: Artemether, Praziquantel, Resistance Schistosomiasis, Sudan

Abstract

Schistosomiasis is a neglected tropical disease (NTD) that remains one of the most prevalent parasitic infections in Africa , S. mansoni and S. haematobium are the most common species that infect humans and the Praziquantel (PZQ) is the drug of choice for treatment despite the recent resistance to it .In this case report, we present an augmenting evidence to support the use of combination regimen of antimalarial drug, Artemether (ART) along with Praziquantel, as an efficient methodology in the treatment of resistant urinary schistosomiasis.